335 related articles for article (PubMed ID: 24407433)
1. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.
Lai JP; Chen ZM; Lok T; Chan OT; Himmelfarb E; Zhai Q; Lin F; Wang HL
J Clin Pathol; 2014 Jun; 67(6):464-9. PubMed ID: 24407433
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
Bioulac-Sage P; Cubel G; Balabaud C; Zucman-Rossi J
Semin Liver Dis; 2011 Feb; 31(1):91-103. PubMed ID: 21344354
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous occurrence of focal nodular hyperplasia and HNF1A-inactivated hepatocellular adenoma: a collision tumor simulating a composite FNH-HCA.
Shih A; Lauwers GY; Balabaud C; Bioulac-Sage P; Misdraji J
Am J Surg Pathol; 2015 Sep; 39(9):1296-300. PubMed ID: 26274031
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma.
Ahmad I; Iyer A; Marginean CE; Yeh MM; Ferrell L; Qin L; Bifulco CB; Jain D
Hum Pathol; 2009 May; 40(5):726-34. PubMed ID: 19157505
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
Choi WT; Ramachandran R; Kakar S
Hum Pathol; 2017 May; 63():1-13. PubMed ID: 28087475
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes.
Bioulac-Sage P; Cubel G; Taouji S; Scoazec JY; Leteurtre E; Paradis V; Sturm N; Nhieu JT; Wendum D; Bancel B; Ramos J; Paraf F; Saint Paul MC; Michalak S; Fabre M; Guettier C; Le Bail B; Zucman-Rossi J; Balabaud C
Am J Surg Pathol; 2012 Nov; 36(11):1691-9. PubMed ID: 23060349
[TBL] [Abstract][Full Text] [Related]
8. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma.
Joseph NM; Ferrell LD; Jain D; Torbenson MS; Wu TT; Yeh MM; Kakar S
Mod Pathol; 2014 Jan; 27(1):62-72. PubMed ID: 23807780
[TBL] [Abstract][Full Text] [Related]
10. Pathological diagnosis of benign hepatocellular nodular lesions based on the new World Health Organization classification.
Kondo F; Fukusato T; Kudo M
Oncology; 2014; 87 Suppl 1():37-49. PubMed ID: 25427732
[TBL] [Abstract][Full Text] [Related]
11. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
12. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
[TBL] [Abstract][Full Text] [Related]
13. [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors].
Bioulac-Sage P; Balabaud C; Zucman-Rossi J
Ann Pathol; 2010 Dec; 30(6):439-47. PubMed ID: 21167430
[TBL] [Abstract][Full Text] [Related]
14. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
de Boer WB; Segal A; Frost FA; Sterrett GF
Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
[TBL] [Abstract][Full Text] [Related]
15. Immunostaining of glutamine synthetase is a sensitive and specific marker for diagnosing focal nodular hyperplasia in needle biopsy.
Tsai JH; Jeng YM; Pan CC; Lu SW; Kuo YJ
Pathology; 2012 Dec; 44(7):605-10. PubMed ID: 22990279
[TBL] [Abstract][Full Text] [Related]
16. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis.
Agnello F; Ronot M; Valla DC; Sinkus R; Van Beers BE; Vilgrain V
Radiology; 2012 Feb; 262(2):511-9. PubMed ID: 22143926
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsy for diagnosis of presumed benign hepatocellular lesions lacking magnetic resonance imaging diagnostic features of focal nodular hyperplasia.
Sannier A; Cazejust J; Lequoy M; Cervera P; Scatton O; Rosmorduc O; Wendum D
Liver Int; 2016 Nov; 36(11):1668-1676. PubMed ID: 26969817
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions.
Grigioni WF; Fiorentino M; D'Errico A; Ponzetto A; Crepaldi T; Prat M; Comoglio PM
Hepatology; 1995 Jun; 21(6):1543-6. PubMed ID: 7768498
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
Shanbhogue AK; Prasad SR; Takahashi N; Vikram R; Sahani DV
Radiology; 2011 Mar; 258(3):673-93. PubMed ID: 21339346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
